Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8536806 | Pharmacology & Therapeutics | 2018 | 59 Pages |
Abstract
Inflammasomes are important in host defense; however, a deregulated activity is associated with a number of inflammatory, immune and metabolic disorders. Furthermore, mutations in inflammasome receptor coding genes are causal for an increasing number of rare autoinflammatory diseases. Biotherapies targeting the products of inflammasome activation as well as molecules that directly or indirectly inhibit inflammasome nucleation and activation are promising therapeutic areas. This review discusses recent advances in inflammasome biology, the molecular pathology of several inflammasomes, and current therapeutic approaches in autoinflammatory diseases and in selected common multifactorial inflammasome-mediated disorders.
Keywords
NBDTRIMAIM2NLRP3P2X7FMFNLRAutoinflammationCAPSTLRNLRX1LRRDAMPASCPYDnucleotide-binding and oligomerization domainNF-κBTNFNLRP1LPSNon-canonical inflammasomeNLRP12mRNADNAROSAdenosine TriphosphateATPdeoxyribonucleic acidinflammasomestripartite motifDanger-associated molecular patternFamilial Mediterranean feverleucine-rich repeatToll-like receptornucleotide-binding domaincaspase recruitment domainpyrin domainmessenger ribonucleic acidCryopyrin-associated periodic syndromesCytokinesendoplasmic reticulumtumor necrosis factornuclear factor-κBlipopolysaccharideGenome-wide association studiesGWASPyrinapoptosis-associated speck-like protein containing a CARDpyroptosisCARDReactive oxygen speciespurinergic receptor
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Fawaz Awad, Eman Assrawi, Camille Louvrier, Claire Jumeau, Sophie Georgin-Lavialle, Gilles Grateau, Serge Amselem, Irina Giurgea, Sonia-Athina Karabina,